ATE515506T1 - Verfahren zur synthese von 2- aminothiazolverbindungen als kinaseinhibitoren - Google Patents
Verfahren zur synthese von 2- aminothiazolverbindungen als kinaseinhibitorenInfo
- Publication number
- ATE515506T1 ATE515506T1 AT08708929T AT08708929T ATE515506T1 AT E515506 T1 ATE515506 T1 AT E515506T1 AT 08708929 T AT08708929 T AT 08708929T AT 08708929 T AT08708929 T AT 08708929T AT E515506 T1 ATE515506 T1 AT E515506T1
- Authority
- AT
- Austria
- Prior art keywords
- synthesis
- kinase inhibitors
- aminothiazole compounds
- aminothiazole
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Oncology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Communicable Diseases (AREA)
- Neurology (AREA)
- Transplantation (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Catalysts (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US88958707P | 2007-02-13 | 2007-02-13 | |
PCT/EP2008/051704 WO2008098949A2 (en) | 2007-02-13 | 2008-02-13 | Process for the synthesis of 2-aminothiazole compounds as kinase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE515506T1 true ATE515506T1 (de) | 2011-07-15 |
Family
ID=39332208
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT08708929T ATE515506T1 (de) | 2007-02-13 | 2008-02-13 | Verfahren zur synthese von 2- aminothiazolverbindungen als kinaseinhibitoren |
Country Status (23)
Country | Link |
---|---|
US (3) | US8153792B2 (de) |
EP (2) | EP2366703B1 (de) |
JP (2) | JP5568312B2 (de) |
KR (1) | KR20090110851A (de) |
CN (2) | CN101657446B (de) |
AR (1) | AR065337A1 (de) |
AT (1) | ATE515506T1 (de) |
AU (1) | AU2008214679A1 (de) |
BR (1) | BRPI0807626B1 (de) |
CA (2) | CA2677586C (de) |
ES (2) | ES2522169T3 (de) |
HR (2) | HRP20110709T1 (de) |
IL (1) | IL200320A0 (de) |
MA (1) | MA31180B1 (de) |
MX (1) | MX2009008665A (de) |
NZ (1) | NZ578944A (de) |
PL (2) | PL2366703T3 (de) |
RU (2) | RU2456285C2 (de) |
SI (2) | SI2118099T1 (de) |
TN (1) | TN2009000342A1 (de) |
TW (1) | TWI406862B (de) |
WO (1) | WO2008098949A2 (de) |
ZA (1) | ZA200905981B (de) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8450302B2 (en) | 2002-08-02 | 2013-05-28 | Ab Science | 2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors |
PT1525200E (pt) | 2002-08-02 | 2008-01-10 | Ab Science | 2-(3-aminoaril)amino-4-aril-tiazóis para o tratamento de doenças |
AR080048A1 (es) | 2010-01-28 | 2012-03-07 | Ab Science | Tratamiento del tumor del estroma gastrointestinal (gist) con masitinib |
AR080096A1 (es) | 2010-02-01 | 2012-03-14 | Ab Science | Tratamiento combinado de cancer de pancreas con gemcitabina y masitinib |
AR080380A1 (es) | 2010-03-09 | 2012-04-04 | Ab Science | Tratamiento de la demencia tipo alzheimer con masitinib |
WO2011131705A1 (en) | 2010-04-20 | 2011-10-27 | Ab Science | Treatment of multiple sclerosis with masitinib |
WO2011151372A1 (en) | 2010-06-02 | 2011-12-08 | Ab Science | Treatment of rheumatoid arthritis with masitinib |
US10045978B2 (en) | 2010-11-05 | 2018-08-14 | Ab Science | Treatment of mastocytosis with masitinib |
US20140147415A1 (en) | 2010-11-05 | 2014-05-29 | Ab Science | Treatment of mastocytosis with masitinib |
WO2012104402A1 (en) * | 2011-02-04 | 2012-08-09 | Ab Science | Treatment of severe persitent asthma with masitinib |
AR085934A1 (es) | 2011-04-08 | 2013-11-06 | Ab Science | Tratamiento de mieloma multiple con masitinib |
BR112015007144A2 (pt) | 2012-10-04 | 2017-12-12 | Ab Science | uso de masitinib para o tratamento de câncer em subpopulações de paciente identificadas usando fatores prognosticadores |
WO2015082496A1 (en) | 2013-12-02 | 2015-06-11 | Ab Science | Use of masitinib for treatment of colorectal cancer |
EP2886543A1 (de) | 2013-12-18 | 2015-06-24 | Sandoz Ag | Kristalline Form von Masitinib |
WO2015185958A1 (en) | 2014-06-02 | 2015-12-10 | Ab Science | Use of an inhibitor of kinase activity, particularly masitinib, for treatment of prostate cancer |
CN105585556A (zh) * | 2014-11-13 | 2016-05-18 | 连云港杰瑞药业有限公司 | 一种伊马替尼的合成方法 |
CN106794179A (zh) * | 2015-07-29 | 2017-05-31 | 苏州晶云药物科技有限公司 | 马赛替尼甲磺酸盐的新晶型及其制备方法 |
CA3000894A1 (en) | 2015-10-05 | 2017-04-13 | Ab Science | Treatment of severe systemic mastocytosis with masitinib |
ES2899929T3 (es) | 2016-03-25 | 2022-03-15 | Ab Science | Uso de masitinib para el tratamiento de una subpoblación de pacientes con esclerosis lateral amiotrófica |
WO2018177854A1 (en) | 2017-03-31 | 2018-10-04 | Sandoz Ag | Crystalline form of masitinib |
US10696638B2 (en) | 2017-12-26 | 2020-06-30 | Industrial Technology Research Institute | Compounds for inhibiting AGC kinase and pharmaceutical compositions comprising the same |
WO2021099616A1 (en) | 2019-11-22 | 2021-05-27 | Ab Science | Masitinib for the treatment of sickle cell disease |
EP3831384A1 (de) | 2019-12-02 | 2021-06-09 | AB Science | Verwendung von masitinib zur behandlung von eosinophilem asthma |
KR20220143020A (ko) | 2020-02-20 | 2022-10-24 | 에이비 사이언스 | 다발 경화증 환자 하위집단의 치료를 위한 마시티닙 |
IL297021A (en) | 2020-04-10 | 2022-12-01 | Ab Science | Use of masitinib to treat the 2019 coronavirus disease (covid-19) |
JP2023554354A (ja) | 2020-12-16 | 2023-12-27 | エービー サイエンス | アルツハイマー病の処置のためのマシチニブ |
KR20240008875A (ko) | 2021-05-17 | 2024-01-19 | 에이비 사이언스 | 거세-저항성 전립선암의 치료를 위한 마시티닙 |
CN115850258B (zh) * | 2022-12-27 | 2024-09-24 | 东北林业大学 | 一种马赛替尼的合成方法 |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3299087A (en) | 1961-04-24 | 1967-01-17 | Geigy Chem Corp | Nu, nu'-bis-(thiazolyl)-phenylenediamines |
EP0983260A2 (de) * | 1997-05-22 | 2000-03-08 | G.D. Searle & Co. | 4-aryl-3 (5)-heteroaryl substituierte pyrazole als inhibitoren der p38 kinase |
CO4940418A1 (es) * | 1997-07-18 | 2000-07-24 | Novartis Ag | Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso |
GB9718913D0 (en) * | 1997-09-05 | 1997-11-12 | Glaxo Group Ltd | Substituted oxindole derivatives |
SK5212000A3 (en) * | 1997-10-27 | 2001-04-09 | Agouron Pharmaceuticals Inc Ag | 4-aminothiazole derivatives, their preparation and their use as inhibitors of cyclin-dependent kinases |
US6114365A (en) * | 1999-08-12 | 2000-09-05 | Pharmacia & Upjohn S.P.A. | Arylmethyl-carbonylamino-thiazole derivatives, process for their preparation, and their use as antitumor agents |
HUP0202682A3 (en) * | 1999-09-10 | 2003-03-28 | Merck & Co Inc | Tyrosine kinase inhibitors, pharmaceutical compositions containing them and their use |
EP1401413B1 (de) | 2001-06-29 | 2006-11-22 | AB Science | Die verwendung von tyrosinkinasehemmer zur behandlung von allergischen erkrankungen |
ATE343415T1 (de) | 2001-06-29 | 2006-11-15 | Ab Science | Die verwendung von c-kit hemmer zur behandlung von entzündlichen darmerkrankungen |
ATE330608T1 (de) | 2001-06-29 | 2006-07-15 | Ab Science | Die verwendung von n-phenyl-2-pyrimidine-amine derivaten zur behandlung von entzündlichen erkrankungen |
US20030091974A1 (en) | 2001-06-29 | 2003-05-15 | Alain Moussy | Method for screening compounds capable of depleting mast cells |
WO2003002105A2 (en) | 2001-06-29 | 2003-01-09 | Ab Science | Use of tyrosine kinase inhibitors for treating bone loss |
WO2003002107A2 (en) | 2001-06-29 | 2003-01-09 | Ab Science | Use of tyrosine kinase inhibitors for treating multiple sclerosis (ms) |
CA2452171A1 (en) | 2001-06-29 | 2003-01-09 | Ab Science | Use of potent, selective and non toxic c-kit inhibitors for treating mastocytosis |
CA2452368A1 (en) | 2001-06-29 | 2003-01-09 | Ab Science | New potent, selective and non toxic c-kit inhibitors |
JP2004536097A (ja) | 2001-06-29 | 2004-12-02 | アブ サイエンス | 自己免疫疾患を治療するためのチロシンキナーゼ阻害剤の使用法 |
EP1401412A2 (de) | 2001-06-29 | 2004-03-31 | AB Science | Verwendung von potenten, selektiven und nontoxischen c-kithemmer zur behandlung von tumorangiogenese |
EP1461032B1 (de) | 2001-09-20 | 2008-07-16 | AB Science | Die verwendung von c-kithemmern zur förderung des haarwuchses |
CA2461181A1 (en) | 2001-09-20 | 2003-05-01 | Ab Science | Use of potent, selective and non-toxic c-kit inhibitors for treating bacterial infections |
WO2003039550A1 (en) | 2001-09-20 | 2003-05-15 | Ab Science | Use of tyrosine kinase inhibitors for whitening human skin and treating melanocyte dysfunction associated diseases |
US20050203098A1 (en) | 2002-02-27 | 2005-09-15 | Alain Moussy | Use of tyrosine kinase inhibitors for treating substance use disorders |
ATE334693T1 (de) | 2002-02-27 | 2006-08-15 | Ab Science | Verwendung von tyrosine-kinase inhibitoren zur behandlung von cns krankheiten |
PL373842A1 (en) * | 2002-05-29 | 2005-09-19 | Amgen Inc. | 2-oxo-1,3,4-trihydroquinazolinyl derivatives for the treatment of cell proliferation-related disorders |
PT1525200E (pt) * | 2002-08-02 | 2008-01-10 | Ab Science | 2-(3-aminoaril)amino-4-aril-tiazóis para o tratamento de doenças |
SE0202462D0 (sv) * | 2002-08-14 | 2002-08-14 | Astrazeneca Ab | Novel use |
CA2515215A1 (en) * | 2003-02-10 | 2004-08-26 | Amgen Inc. | Vanilloid receptor ligands and their use in treatments |
CA2517308A1 (en) | 2003-02-27 | 2004-09-10 | Ab Science | Tailored treatment suitable for different forms of mastocytosis |
FR2854158B1 (fr) * | 2003-04-25 | 2006-11-17 | Sanofi Synthelabo | Derives de 2-acylamino-4-phenylethiazole, leur preparation et leur application en therapeutique |
CN1860118A (zh) * | 2003-07-29 | 2006-11-08 | Irm责任有限公司 | 作为蛋白激酶抑制剂的化合物和组合物 |
EP1653934B1 (de) | 2003-08-15 | 2008-05-14 | AB Science | Verwendung von c-kit-inhibitoren für die behandlung von typ-2-diabetes |
US7363881B2 (en) | 2003-11-06 | 2008-04-29 | Nova-Tech Engineering, Inc. | Beak treatment with tongue protection |
CA2551529C (en) * | 2003-12-25 | 2011-02-01 | Nippon Shinyaku Co., Ltd. | Amide derivative and medicine |
US7650848B2 (en) * | 2004-02-17 | 2010-01-26 | University Of Florida Research Foundation, Inc. | Surface topographies for non-toxic bioadhesion control |
WO2005115385A1 (en) * | 2004-05-24 | 2005-12-08 | Ab Science | Use of c-kit inhibitors for treating acne |
TW200702876A (en) * | 2005-07-04 | 2007-01-16 | Avermedia Tech Inc | Projector device capable of sychronously encoding audio and video to become AV sychronous paly file |
-
2008
- 2008-02-13 MX MX2009008665A patent/MX2009008665A/es active IP Right Grant
- 2008-02-13 WO PCT/EP2008/051704 patent/WO2008098949A2/en active Application Filing
- 2008-02-13 NZ NZ578944A patent/NZ578944A/en unknown
- 2008-02-13 ES ES11170200.7T patent/ES2522169T3/es active Active
- 2008-02-13 CA CA2677586A patent/CA2677586C/en active Active
- 2008-02-13 RU RU2009132186/04A patent/RU2456285C2/ru active
- 2008-02-13 CN CN2008800049044A patent/CN101657446B/zh active Active
- 2008-02-13 EP EP11170200.7A patent/EP2366703B1/de active Active
- 2008-02-13 KR KR1020097016822A patent/KR20090110851A/ko not_active Application Discontinuation
- 2008-02-13 ES ES08708929T patent/ES2369617T3/es active Active
- 2008-02-13 CN CN201310141370.2A patent/CN103342701B/zh active Active
- 2008-02-13 US US12/526,827 patent/US8153792B2/en active Active
- 2008-02-13 BR BRPI0807626-0A patent/BRPI0807626B1/pt active IP Right Grant
- 2008-02-13 SI SI200830399T patent/SI2118099T1/sl unknown
- 2008-02-13 TW TW097105021A patent/TWI406862B/zh not_active IP Right Cessation
- 2008-02-13 SI SI200831294T patent/SI2366703T1/sl unknown
- 2008-02-13 PL PL11170200T patent/PL2366703T3/pl unknown
- 2008-02-13 AT AT08708929T patent/ATE515506T1/de not_active IP Right Cessation
- 2008-02-13 CA CA2970628A patent/CA2970628C/en active Active
- 2008-02-13 AR ARP080100620A patent/AR065337A1/es active IP Right Grant
- 2008-02-13 PL PL08708929T patent/PL2118099T3/pl unknown
- 2008-02-13 EP EP08708929A patent/EP2118099B1/de active Active
- 2008-02-13 JP JP2009549405A patent/JP5568312B2/ja active Active
- 2008-02-13 AU AU2008214679A patent/AU2008214679A1/en not_active Abandoned
-
2009
- 2009-08-10 IL IL200320A patent/IL200320A0/en unknown
- 2009-08-11 MA MA32161A patent/MA31180B1/fr unknown
- 2009-08-11 TN TNP2009000342A patent/TN2009000342A1/fr unknown
- 2009-08-28 ZA ZA2009/05981A patent/ZA200905981B/en unknown
-
2011
- 2011-10-05 HR HR20110709T patent/HRP20110709T1/hr unknown
-
2012
- 2012-03-08 US US13/415,249 patent/US8492545B2/en active Active
- 2012-04-12 RU RU2012114234/04A patent/RU2491286C1/ru active
-
2013
- 2013-05-10 US US13/891,639 patent/US8940894B2/en active Active
- 2013-05-30 JP JP2013113789A patent/JP5784073B2/ja active Active
-
2014
- 2014-10-15 HR HRP20140986AT patent/HRP20140986T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE515506T1 (de) | Verfahren zur synthese von 2- aminothiazolverbindungen als kinaseinhibitoren | |
ATE538111T1 (de) | Verfahren zur synthese von 5- alkoxymethylfurfuralethern | |
ATE474845T1 (de) | Verfahren zur synthese von saccharose-6-estern | |
ATE459416T1 (de) | Verfahren zur beseitigung von endokrin wirksamen verbindungen | |
HK1259148A1 (zh) | 用作atr激酶抑制劑的化合物 | |
CY2017042I1 (el) | Ενωσεις πυρρολοπυριμιδινης ως αναστολεις cdk | |
ATE540931T1 (de) | Verfahren zur synthese organischer verbindungen | |
SMT201600267B (it) | Inibitori di syk imidazopirazinici | |
DE602008004764D1 (de) | Verfahren zur hydrokonversion von schwerölen | |
SI2021335T1 (sl) | Heterocikliäśne spojine kot zaviralci c-fms kinaze | |
ATE554078T1 (de) | Synthese von 11-beta-hydroxysteroid-dehydrogenase-1-hemmern | |
DE602006014670D1 (de) | Verfahren zur doppelbindungs-hydroisomerisierung von butenen | |
HK1161260A1 (zh) | 用作 激酶抑制劑的化合物 | |
SMT201400133B (it) | Composti e composizioni come inibitori di protein chinasi | |
ATE551342T1 (de) | Heterocyclische verbindungen und zusammensetzungen als c-kit- und pdgfr- kinasehemmer | |
ATE487709T1 (de) | Verfahren zur synthese von 5-(methyl-1h-imidazol- 1-yl)-3-(trifluormethyl)benzolamin | |
ATE486853T1 (de) | Synthese von acylaminoalkenylenamiden als substanz-p-antagonisten | |
ATE543816T1 (de) | Azacycloalkanderivate als inhibitoren von stearoyl-coenzym-a-delta-9-desaturase | |
DK2257532T3 (da) | Fremgangsmåde til regioselektiv syntese af 1-alkyl-3-haloalkyl-pyrazol-4-carboxylsyrederivater | |
ATE478849T1 (de) | 4-anilinochinolin-3-carbonsäureamide als csf-1r- kinaseinhibitoren | |
DE602007008201D1 (de) | Verfahren zur qualitätskontrolle von speichermedien | |
DE602005024305D1 (de) | Verfahren zu synthese von glycolonitril | |
ATE460408T1 (de) | Verfahren zur synthese von strontiumranelat und seinen hydraten | |
ATE483690T1 (de) | Verfahren zur synthese von 5-(methyl-1h-imidazol- 1-yl)-3-(trifluormethyl)-benzeneamin | |
DE112009001327A5 (de) | Verfahren zur stereoselektiven Synthese von Phosphor-Verbindungen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |